

PERSONAL INFORMATION

Mauro Magnani



Via Cà Adelia, 6 – Loc. Torre - 61029 Urbino (PU)
 +39 0722 305211 +39 338 6181791
mauro.magnani@uniurb.it

Sex Male | Date of birth 09/04/1953 | Nationality Italian

WORK EXPERIENCE

1986 - present **Full Professor of Biochemistry and Director School of Biology and Biotechnology**
University of Urbino, Italy

EDUCATION AND TRAINING

- 1982-1986 **Associate Professor**
University of Urbino
- Assistant Professor**
University of Urbino
- 1983 **Visiting Professor**
Department of Biology, Haifa, Israel
- 1980 **Visiting Researcher**
Department of Biochemistry, University of Birmingham
- 1976 **Visiting Professor**
Department of Biology, Haifa, Israel
- Visiting Researcher**
Department of Biochemistry, University of Birmingham

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C2	C1	C1	C1
	Replace with name of language certificate. Enter level if known.				
French	A2	A2	A1	A1	A1
	Replace with name of language certificate. Enter level if known.				

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user
Common European Framework of Reference for Languages

Communication skills good communication skills gained through my experience as chair and speaker at several conferences and workshops

Organisational / managerial skills	Vice-Rector University of Urbino 2011-2019; Dean School of Biology and Biotechnology, University of Urbino; Past President Interuniversity Consortium for Biotechnology (CIB); Past President Italian Society of Biochemistry and Molecular Biology; Member of the Council of the Federation of European Biochemical Societies; Chief Scientific Officer Diatheva; Member of the Scientific Committee SZN, Napoli;
Job-related skills	<ul style="list-style-type: none">▪ leadership (currently responsible for a team of 15 people)▪ Technical Director nominated by the "Agenzia Italiana del Farmaco, AIFA" with n. AIDT-19/2005
Computer skills	<ul style="list-style-type: none">▪ good command of Microsoft Office™ tools
Driving licence	<ul style="list-style-type: none">▪ Category B

ADDITIONAL INFORMATION

REVIEWER: Nature Biotechnology; Biotechnology Advances; Trends in Biotechnology; Drugs; Leukemia; European Journal Haematology; Biotechnology and Applied Biochemistry; Biochimica et Biophysica Acta; Blood; Journal of Cellular Engineering; Journal of Internal Medicine; Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology; Mechanisms of Ageing and Development; Antiviral Research; Journal of Chromatography; Journal of Biological Regulators and Homeostatic Agents; Life Sciences; Biochemistry; International Journal of Biochemistry and Cell Biology; Human Gene Therapy; European Journal of Biochemistry; Clinical Pharmacokinetics; Autoimmunity; Oncogene; Analytical Biochemistry; The Hematology Journal; Talanta, Sports Medicine, Cell Biology and Toxicology; Letters in Applied Microbiology; Haematologica; J. Controlled Release; Gene; Nanomedicine; Harmful Algae; Analytica Chimica Acta, AIDS Research and Treatment, Plos One, AAPS Pharm SciTech, etc.

Editorial Board: Current Drug Targets; The Open Pharmacology Journal; Biotechnology; World Journal of Pharmacology; New Horizons in Translational Medicine, Frontiers in Physiology: Red Blood Cell Physiology Section; Associate Editor Frontiers in Bioengineering;

National Register of Biologists Included in the official list of professional biologists with n. 017484.

- Publications** Over 500 articles published in international refereed scientific journal for a complete list see PubMed
H index = 70 Citations = 20,707 i10-index 404
<https://scholar.google.it/citations?user=WY1MmwUAAAAJ&hl=it&authuser=1>
RG score =50.34
https://www.researchgate.net/profile/Mauro_Magnani2
- Co-editor (books)** Red Blood Cell Aging, Plenum Press, N.Y., 1991, pp. 383
The Use of Resealed Erythrocytes as Carriers and Bioreactors, Plenum Press, N.Y., 1992, 3 361
Erythrocytes Engineering for Drug Delivery and Targeting, Landes Bioscience, 2002
- Patents**
- 1) European Patent EP 0517986B1
M. Magnani, L. Rossi "Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions"
US Patent 5,753,221
M. Magnani, L. Rossi "Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions"
CA2102619 A1
"Erythrocytes transformes, leur procede de preparation, et utilisation dans les compositions pharmaceutiques"
 - 2) US Patent N. 6.139.836 DE69732225D1, DE69732225T2, EP0882448A1, EP0882448B1
Mauro Magnani, Ivo Panzani, Leonardo Bigi, Andrea Zanella "Method of encapsulating biologically active agents within erythrocytes, and apparatus therefor"
 - 3) European Patent N. EP98830479.6
M. Magnani, G. Brandi, A. Fratemale, A. Casabianca "Pharmaceutical composition or composition package containing a pyrimidine nucleoside analogue and a purine nucleoside analogue"
 - 4) Brevetto C.N.R. N. RM92 A 000377
M. Magnani "Antigeni legati alla superficie esterna di eritrociti e procedimento per la loro preparazione"
 - 5) Brevetto C.N.R. N. RM 93 A 000474
M. Magnani "Eritrociti incorporanti alcool ossidasi e loro uso nelle intossicazioni da metanolo"
 - 6) Brevetto C.N.R.
M. Magnani, L. Rossi, G. Brandi, E. Millo, G. Damonte, U. Benatti, A. De Flora "Profarmaco di acyclovir e suo uso in composizioni farmaceutiche"
 - 7) Brevetto di Invenzione N. MI2002A01196 – 06/06/1996 EP1395595A1, EP1395595B1, US7645788, US20040214876, WO2002098881A1, CA2449877 A1US Patent n. 7,645,788 B2
Granted
M. Magnani, C. Fiorucci, P. Filippone, G. Brandi, M. Paiardini. "Derivato tetramerico dell'indol-3 carbinolo ad attività anticancerogena e metodo di sintesi del derivato stesso". "Tetrameric derivative of indole-3-carbinol with anti-carcinogenic activity and method of synthesis of said derivative"
 - 8) Brevetto di Invenzione N. TO2001A01077 – 16/11/2001
M. Magnani, F. Graziano, A. Ruzzo "Mutazioni della linea germinale nel promotore del gene della E-caderina e metodi di diagnosi per individuare una maggiore suscettibilità al carcinoma gastrico".
WO2003042409A2, WO2003042409A8 "Germ line mutation in the promoter of e-caderine and diagnostic method for finding a greater susceptibility to gastric carcinoma"
 - 9) US20070270349 A1DE602004029191D1, EP1701973A1, EP1701973B1, US20120165248, WO2005063795A1 granted
U. Benfatti, G. Brandi, E. Garaci, M. Magnani, E. Millo, AT. Palamara, L. Rossi
"Derivati del Glutazione e loro utilizzi per il trattamento delle malattie virali" "Glutathione Derivatives and Their Uses for the Treatment of Viral Diseases"
 - 10) EP2043697A2, US20100061937, WO2008003524A2
M. Magnani, A. Antonelli . "Delivery of contrasting agents for magnetic resonance imaging"
 - 11) CA2763695A1, EP2437736A2, US8734787, US20120141540, PCT/EP2010/003783
M. Magnani, L. Rossi, S. Biagiotti and M. Bianchi "Drug Delivery Systems"
New Zealand Patent Application No. 596813 (granted)
 - 12) CN102007141A, US20110319593, WO2009098094A1EP20090708997
B. Ensoli, M. Magnani
Process for the production of biologically active hiv-1 tat protein
 - 13) US 20140202857 A1 EP2715344A1, WO2012160584A1
Ugo Valbusa, Luca Repetto, Giuseppe Firpo, Valentina Mussi, Paola Fanzio, Chiara Manneschi, Gian Paolo Tonini, Paola Scaruffi, Sara Stigliani, Michele Menotta, Mauro Magnani "Device and single-molecule analysis method by means of detection of the collisions of a target molecule on functionalized nanopores"

14) RM2015A000022
 M. Magnani, S. Biagiotti, M. Menotta
 "Metodo di valutazione della risposta di pazienti affetti da atassia telangiectasia al trattamento con glucocorticoidi.

15) 102022000002645 14/09/2022
 Replace with first name(s) not already mentioned. Specify in what context they were mentioned.
 MENOTTA Miroslava Italia RICCI Anastasia Italia BIANCUCCI Federica Italia MAGNANI Mauro Italia
 VARIANTI DELLA PROTEINA UMANA ATM PER IL TRATTAMENTO
 DI PATOLOGIE CORRELATE A MUTAZIONI DEL GENE ATM

16) 102021000013814 28/06/2021
 Magnani Mauro et al. Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine

Current Research	Red blood cell as drug-delivery systems and as circulating bioreactors; Development and delivery of biologics; Drug efficacy, resistance and drug toxicity; Pharmacogenetic profiling; Modulation of NF-κB and gene expression by oligonucleotide decoy; Nanomaterials in drug delivery and imaging; Recombinant vaccine production; HIV-persistence and reservoirs
Honours and awards	Awarded "Genomic Pioneers" by HUGO and Ocimum (2008) Member of "Accademia Raffaello" (2008) Awarded "Genomic Pioneers" by HUGO (2008) Paul Harris Fellow from The Rotary Foundation (2007) Included in the list of "Top Italian Scientists" (2009) World's Top 2% Scientists List produced by John P. A. Ioannidis (Stanford University) et al, 2020 Member of Scientific Committee Biogen; International Advisory Board Center for Life Sciences Nazarbayev University, Astana. Member of the National Committee for Biosafety, Biotechnology and Life Sciences, Presidency of the Italian Government
Referree	Different Programmes of the E.U. The International Science Foundation (U.S.A.) Czech Academy of Sciences The Executive Agency for Higher Education Research, Development and Innovation Funding of Romania Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) Dutch Cancer Society Swiss National Science Foundation Innovation and Technology Commission the Government of Hong Kong Israeli Ministry of Science, Technology Target Project "Biotechnology" of the National Research Council (C.N.R.)
Projects	(Most recent) Mauro Magnani (PI) MAGneTISe Era-Net EuroNanomed III (FIRST 2017 - IGRUE) 01/05/2018- 30/04/2021 Mauro Magnani (PI) IEDAT H2020 01/04/2016-28/02/2021 Mauro Magnani (PI) Piattaforma di ricerca collaborativa nell'ambito della medicina personalizzata: farmaci, diagnostici e nuovi approcci terapeutici, Marche Biobank POR FESR 11/12/2019-10/12/2022 Mauro Magnani (PI) Progetto di Ricerca Finalizzata (29/RF-2016-02364744) 12/10/18-11/10/21 Mauro Magnani (PI) PRIN 2017 19/08/19 18/08/22 Mauro Magnani (PL) FISR 2019 04835 2020-2023 Board Member of the Project "Patologia clinica e terapia dell'infezione da HIV" of the Italian Ministry of Health PRIN and FIRB Projects of Italian Ministry of University and Research; Member of Committee Post Genoma (C.N.R.) Member "Comitato Educazione, Formazione e Ricerca" Ministero Politiche Comunitarie Member "Comitato Nazionale per la Biosicurezza e le Biotecnologie" Presidenza Consiglio dei Ministri; Include in the "Albo degli Esperti" of M.I.U.R. and EU Eureka projects Biotechnology programmes of the regions Piemonte, Sardegna, Emilia Romagna, Trentino, Campania.

Biochemical Society
Italian Biochemical Society (Past President and member of the board)
Int. Soc. For The Use of Resealed Erythrocytes (President 1991-1993)
Red Cell Research Group; European Haematology Association; International Society for Antiviral Research
American Society of Human Genetics
International Society for Antiviral Research
International Society for Nucleosides
Nucleotides and Nucleic Acids
Member of the "Consiglio di Amministrazione" University of Urbino

Director Interuniversity Consortium for Biotechnology (CIB) (1998-2005) (From November 2006
Member of the board and Vice-Director)
Vice Rector of the University of Urbino (2001-2009)
Member of the administrative council of the "Stazione Zoologica Anton Dohrn" Napoli, nominated by
the Minister of University and Research, Rome (From Sept 2011)

Entrepreneurial Activities

Co-founder of Diatheva SrL (www.diatheva.com)
Co-founder of EryDel SpA (www.erydel.com) Start-up of the year 2018;
▪ Category B

Other Assignments

Technical Director nominated by the "Agenzia Italiana del Farmaco, AIFA" with n. AIDT-19/2005

Place and Date: Urbino February 16, 2022

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV

Signature:

